In relation to this, we performed a thorough data assessment in terms of: (i) tumor biopsy and tumor cell content; (ii) variant calling quality of both primary and matched metastatic disease samples; (iii) a re-evaluation of low confidence or unfiltered variants; and (iiii) the absence of CNAs in TP53 genes. This evidence concerns the gene TP53 and neoplasm.